Home
About
Overview
Sharing Data
ORCID
Help
History (72)
In vivo demonstration of inflammatory mediator release following nasal challenge with antigen.
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
Patient safety outcomes after two years of an enhanced internal medicine residency clinic handoff.
Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions.
Randomized phase II trials: a long-term investment with promising returns.
See All 72 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Randomized phase II trials: a long-term investment with promising returns.
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
View in:
PubMed
subject areas
Antineoplastic Agents
Chemotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Endpoint Determination
Evidence-Based Medicine
Health Resources
Humans
Life Expectancy
Molecular Targeted Therapy
Patient Selection
Randomized Controlled Trials as Topic
Reproducibility of Results
Research Design
Sample Size
Selection Bias
Time Factors
Treatment Failure
authors with profiles
Mark Ratain